The Federal Trade Commission said the three companies' practices have artificially inflated list prices for insulin.
At its annual sellers’ conference, hosted in Seattle this week, Amazon continually told the thousands of independent vendors ...
The Federal Trade Commission has accused three major pharmacy benefit managers of inflating insulin prices, the agency said ...
The Federal Trade Commission alleges that pharmacy benefits managers prioritized high rebates from drug makers for insulin over lower prices for consumers, leading to inflated out-of-pocket costs.
In the second quarter, federal and state antitrust enforcers continued their intense scrutiny of consolidation in the healthcare market ...
The federal government is suing some pharmacy benefit managers over a system of drug rebates that regulators say has made the ...
1h
Missouri healthcare worker who had contact with a hospitalized patient infected with bird flu developed mild respiratory ...
The Federal Trade Commission (FTC) on Friday sued the three largest pharmacy benefit managers (PBMs) for engaging in alleged ...
The federal government is suing some big pharmacy benefit managers over a system of drug rebates that regulators say has made ...
Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug ...
The Federal Trade Commission sued the drug middlemen that health plans use to keep a lid on drug spending, accusing the firms ...
PBMs, like Optum Rx, are the key counterweight to pharmaceutical companies’ otherwise unchecked monopoly power to set and raise drug prices.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback